|Articles|June 15, 2002
- BioPharm International-06-01-2002
- Volume 15
- Issue 6
Inside Washington: Safety, Risk, and Biotechnology Regulation
Author(s)Jill Wechsler
by Jill Wechsler Concerns about product safety and stiffer FDA regulation of manufacturers may be drying up the biotech pipeline
Advertisement
Articles in this issue
over 23 years ago
Negotiating and Structuring Strategic Alliancesover 23 years ago
Finding Funding in Biotechnology: Keeping the Companies Aliveover 23 years ago
Stem Cells and Xenotransplantation: Ethics, Patents, and Politicsover 23 years ago
Unlocking the Value of R&D: Managing the Risksover 23 years ago
Viewpoint: United Kingdom highlights biomanufacturing capabilitiesover 23 years ago
Criminal Penalties for Theft of Biological MaterialNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5